JPRN-UMIN000022996
Completed
未知
Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial Sarcoidosis
The Department of Cardiology, Nagoya University Graduate School of Medicine0 sites50 target enrollmentJuly 4, 2016
ConditionsMyocardial sarcoidosis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Myocardial sarcoidosis
- Sponsor
- The Department of Cardiology, Nagoya University Graduate School of Medicine
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The patients with myelosuppression, chronic liver dysfunction, chronic kidney disease and infection.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
FDG-PET study for pulmonary MAC and CPAJPRN-jRCTs071190035Takazono Takahiro15
Recruiting
Not Applicable
FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer.Esophageal cancerJPRN-UMIN000002249Osaka Medical Center for Cancer and Cardiovascular Diseases30
Active, not recruiting
Not Applicable
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.Advanced stage Hodgkin's lymphomaMedDRA version: 15.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-005473-22-DKEORTC570
Not yet recruiting
Phase 3
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group and the Polish Lymphoma Research GroupAdvanced stage Hodgkin Lymphoma10025319NL-OMON39829European Organisation for Research in Treatment of Cancer (EORTC)190
Active, not recruiting
Phase 1
Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.Advanced stage Hodgkin's lymphomaMedDRA version: 14.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-005473-22-BEEORTC570